Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
Saved in:
| Title: | Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1. |
|---|---|
| Authors: | Mukherjee D; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Romano E; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Walshaw R; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Zeef LAH; Bioinformatics Core Facility, Michael Smith Building, The University of Manchester, Manchester, UK., Banyard A; Mass and Flow Cytometry Core Facility, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK., Kitcatt SJ; Scientific Computing Core Facility, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK., Cheadle EJ; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Tuomela K; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Pendharkar S; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Al-Deka A; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Salerno B; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Raby S; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Mills IG; Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.; Patrick G. Johnston Centre for Cancer Research, Queen's University of Belfast, Belfast, UK., Honeychurch J; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK., Illidge TM; Targeted Therapy Group, Division of Cancer Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK. |
| Source: | Oncoimmunology [Oncoimmunology] 2023 Jun 15; Vol. 12 (1), pp. 2223094. Date of Electronic Publication: 2023 Jun 15 (Print Publication: 2023). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2162-402X |
|---|---|
| DOI: | 10.1080/2162402X.2023.2223094 |
